Clinical Trials Logo

Clinical Trial Summary

Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. Recently, a randomized study of Pomalidomide and dexamethasone conducted in compared with placebo and dexamethasone showed that pomalidomide can improve survival of this group of patients. As a result, pomalidomide is now approved by the FDA and EMA for use in patients with relapsed/refractory myeloma previously treated with bortezomib and lenalidomide. We have conducted a study using Pomalidomide plus Dexamethasone (PD) in Asian patients, which showed good efficacy and safety profile. More important for patients with suboptimal response to PD will achieve a clinically meaningful response with the addition of oral cyclophosphamide (PCD). In the United States, a small randomised phase 2 study of PCD versus PD showed that PCD have a higher response rates, produce deeper response and correspondingly longer progression free survival. There is till date no randomised phase 3 study between these regimens. This will be important to determine what is the best combination including pomalidomide for use in relapse myeloma.


Clinical Trial Description

In this study, we will prospectively enrol 120 Asian patients with relapsed myeloma after prior treatment with bortezomib and lenalidomide, and randomised them between PCD and PD (60 in each arms). Centers in Singapore, Korea, Taiwan, and Hong Kong will participate in this study.

Pomalidomide is a new immunomodulatory drug, which has been shown to be active in myeloma patients who relapse after bortezomib and lenalidomide. A recent phase III study comparing pomalidomide plus dexamethasone with placebo plus high dose dexamethasone in patients with prior exposure to bortezomib and lenalidomide, showed that the use of pomalidomide significantly improve the overall survival of these patients. In an Asian study, it appears that the addition of cyclophosphamide can induce further response in patients without a response to PD. In the United States, a small randomised phase 2 study of PCD versus PD showed that PCD have a higher response rates, produce deeper response and correspondingly longer progression free survival. Our hypothesis is therefore that PCD will be better than PD and should be the standard pomalidomide containing regimen for relapse myeloma patients. This combination will also be highly relevant to Asian patients because cyclophosphamide is a relatively cheap drug and the combination will be cost effective if proven to be better than PD.

Rationale for the Study Purpose There is a relative lack of data on the efficacy and tolerability of PCD in Asian Patients. The current study will also allow us to test if PCD is better than PD in the treatment of relapse myeloma patients.

Rationale for Study Population The study population will be myeloma patients who have relapsed following prior treatment with bortezomib and lenalidomide. Pomalidomide is the current approved treatment choice for this group of patients and a common indication for us in Asia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03143049
Study type Interventional
Source National University Hospital, Singapore
Contact Wee Joo Chng
Phone 6779 5555
Email mdccwj@nus.edu.sg
Status Recruiting
Phase Phase 3
Start date September 13, 2017
Completion date June 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT01775553 - Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Phase 2
Recruiting NCT05243212 - Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma Phase 1/Phase 2
Recruiting NCT04302324 - A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab Phase 2
Recruiting NCT04143932 - Multiple Myeloma Turkish Prospective Patient Registry
Active, not recruiting NCT05113342 - Descartes-25 in Relapsed/Refractory Multiple Myeloma Phase 1
Recruiting NCT05789303 - Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Phase 2
Withdrawn NCT04918511 - A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma Phase 1
Recruiting NCT05742217 - A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
Recruiting NCT06138275 - Elranatamab in R/R Multiple Myeloma Phase 2
Recruiting NCT05430945 - A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma Early Phase 1
Recruiting NCT05431608 - A Study of MCARH109 and MCARH125 in People With Multiple Myeloma Phase 1
Not yet recruiting NCT06171685 - Horizon Adaptive Platform Trial Evaluating Therapies in RRMM Phase 2
Recruiting NCT05117008 - Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 2
Recruiting NCT05150522 - B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
Withdrawn NCT04355039 - INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT04670055 - A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma Early Phase 1
Not yet recruiting NCT04541368 - A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy Early Phase 1
Recruiting NCT04004338 - Carfilzomib in Combination for the Treatment of RR MM